Proteomic approach toward determining the molecular background of pazopanib resistance in synovial sarcoma

Pazopanib, a multitarget tyrosine kinase (TK) inhibitor, has been approved for treatment of soft tissue sarcoma. Elucidation of the molecular background of pazopanib resistance should lead to improved clinical outcomes in sarcomas; accordingly, we investigated this in synovial sarcoma using a proteo...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Zhiwei, Shiozawa, Kumiko, Kondo, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752544/
https://www.ncbi.nlm.nih.gov/pubmed/29312631
http://dx.doi.org/10.18632/oncotarget.22730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752544/
https://www.ncbi.nlm.nih.gov/pubmed/29312631
http://dx.doi.org/10.18632/oncotarget.22730

Ejemplares similares